Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

1.75
-1.4200-44.79%
Post-market: 1.750.00000.00%19:59 EDT
Volume:112.36M
Turnover:199.07M
Market Cap:584.39M
PE:-1.36
High:1.99
Open:1.94
Low:1.65
Close:3.17
Loading ...

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating

MT Newswires Live
·
03 Mar

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
01 Mar

Iovance Shares Fall After Sales of Cancer Drug Miss Estimate

Dow Jones
·
01 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Reports Surge in Q4 Revenue to US$74M with Improved Losses

Simply Wall St.
·
01 Mar

Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating

MT Newswires Live
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges Nearly 28% as Disappointing Earnings and Guidance Spook Investors

Stock Track
·
28 Feb

Stock Track | Iovance Biotherapeutics Plummets 27.66% on Disappointing Q4 Results and Cash Burn Outlook

Stock Track
·
28 Feb

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty

Zacks
·
28 Feb

Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
28 Feb

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 17.49% in Pre-Market After Q4 Earnings Miss and Disappointing Guidance

Stock Track
·
28 Feb

Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ...

GuruFocus.com
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Iovance Biotherapeutics Inc : Baird Cuts Target Price to $20 From $24

THOMSON REUTERS
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 16.54% as Q4 Earnings and Guidance Disappoint

Stock Track
·
28 Feb

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb